Author:
Fan Jiangqing,Lei Wenpu,Wang Lulu,Ge Weihong
Abstract
AbstractThe determinants of roxadustat treatment failure in renal anemia remain elusive. This study sought to develop a nomogram for predicting the risk of treatment failure of roxadustat in peritoneal dialysis (PD) with renal anemia. A retrospective cohort analysis from January 1, 2019, to January 31, 2023, included 204 PD patients with renal anemia, stratified by attainment group (Hb ≥ 110 g/L, n = 103) or non-attainment (Hb < 110 g/L, n = 101) within 1 year treatment. Univariate and multivariate Cox proportional hazards regressions were employed to ascertain predictive factors and construct the nomogram. Nomogram efficacy was evaluated via C-index, time-dependent ROC, calibration plots, and decision curve analysis, with internal validation via tenfold cross-validation and 1000 bootstrap resampling iterations. The study identified PD duration, serum transferrin, cardiovascular comorbidities, and stains as significant predictors. The nomogram demonstrated moderate discrimination at 6 months (AUC: 0.717) and enhanced predictive accuracy at 12 months (AUC: 0.741). The predicted and actual risk probabilities were concordant, with clinical net benefits observed at six-month (8 to 53%) and twelve-month (27 to 84%) risk thresholds. This nomogram is a valuable tool for effectively predicting non-attainment risk and facilitating personalized management of renal anemia in PD patients treated with roxadustat.
Funder
the Hospital Pharmacy Research Foundation of Changzhou Siyao Hospital and Nanjing Pharmaceutical Association
the Fundamental Research Funds for the Central Universities
Jiangsu Research Hospital Association for Precision Medication
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Fishbane, S. & Coyne, D. W. How I treat renal anemia. Blood 136, 783–789 (2020).
2. Dhillon, S. Roxadustat: First global approval. Drugs 79, 563–572 (2019).
3. National Medical Products Administration. New drug Roxadustat capsules for the treatment of renal anemia granted market approval. https://www.nmpa.gov.cn/yaopin/ypjgdt/20181218092001170.html (2018).
4. Sugahara, M., Tanaka, T. & Nangaku, M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol. Ther. 239, 108272 (2022).
5. Locatelli, F. & Del Vecchio, L. Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: From theoretical superiority to clinical noninferiority compared with current ESAs?. J. Am. Soc. Nephrol. 33, 1966–1979 (2022).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献